Morepen Laboratories Intrinsic Value
Morepen Laboratories (MOREPENLAB) median intrinsic value is ₹52.15 from 9 valuation models (range ₹13–₹106), vs current price ₹42.22 — +23.5% upside (Trading Below Calculated Value), margin of safety 19.0%. Browse MOREPENLAB income statement for revenue, profit, balance sheet and cash flow data.
MOREPENLAB Valuation Methods Summary — DCF, Graham Number & P/E
Morepen Laboratories intrinsic value across 9 models vs current price ₹42.22 — upside/downside and value range per method. Also explore MOREPENLAB price movement history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹24.64 | ₹19.71 - ₹29.57 | -41.6% | EPS: ₹1.12, Sector P/E: 22x |
| Book Value Method | asset | ₹105.55 | ₹95.00 - ₹116.11 | +150.0% | Book Value/Share: ₹107.91, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹84.44 | ₹76.00 - ₹92.88 | +100.0% | Revenue/Share: ₹179.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹84.44 | ₹76.00 - ₹92.88 | +100.0% | EBITDA: ₹132.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹27.01 | ₹21.61 - ₹32.41 | -36.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹12.67 | ₹11.40 - ₹13.94 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹17.30 | ₹15.57 - ₹19.03 | -59.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹58.18 | ₹52.36 - ₹64.00 | +37.8% | ROE: 5.4%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹52.15 | ₹46.94 - ₹57.37 | +23.5% | EPS: ₹1.12, BVPS: ₹107.91 |
MOREPENLAB Intrinsic Value vs Market Price — All Valuation Models
Morepen Laboratories fair value range ₹13–₹106 vs current market price ₹42.22 across 9 valuation models. For current market price and key ratios, visit Morepen Laboratories share price screener.
MOREPENLAB Intrinsic Value Analysis — Undervalued or Overvalued?
Morepen Laboratories median intrinsic value ₹52.15, current price ₹42.22 — Trading Below Calculated Value by 23.5%, margin of safety 19.0%.
What is the intrinsic value of MOREPENLAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Morepen Laboratories (MOREPENLAB) is ₹52.15 (median value). With the current market price of ₹42.22, this represents a +23.5% variance from our estimated fair value.
The valuation range spans from ₹12.67 to ₹105.55, indicating ₹12.67 - ₹105.55.
Is MOREPENLAB undervalued or overvalued?
Based on our multi-method analysis, Morepen Laboratories (MOREPENLAB) appears to be trading below calculated value by approximately 23.5%.
MOREPENLAB Financial Health — Key Ratios vs Industry Benchmarks
Morepen Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.74 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.4% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.11x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
MOREPENLAB Cash Flow Quality — Operating & Free Cash Flow
Morepen Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹32 Cr | ₹-129 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹73 Cr | ₹32 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹-91 Cr | ₹-115 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-60 Cr | ₹-76 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹51 Cr | ₹16 Cr | Positive Free Cash Flow | 7/10 |